187 related articles for article (PubMed ID: 26567733)
21. The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review.
Rice L; Bisdas S
Eur J Radiol; 2017 Sep; 94():16-24. PubMed ID: 28941755
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography diagnosis of Alzheimer's disease.
Coleman RE
Neuroimaging Clin N Am; 2005 Nov; 15(4):837-46, x. PubMed ID: 16443494
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.
Smailagic N; Lafortune L; Kelly S; Hyde C; Brayne C
J Alzheimers Dis; 2018; 64(4):1175-1194. PubMed ID: 30010119
[TBL] [Abstract][Full Text] [Related]
25. Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease.
Lu D; Popuri K; Ding GW; Balachandar R; Beg MF;
Med Image Anal; 2018 May; 46():26-34. PubMed ID: 29502031
[TBL] [Abstract][Full Text] [Related]
26. A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment.
Garibotto V; Trombella S; Antelmi L; Bosco P; Redolfi A; Tabouret-Viaud C; Rager O; Gold G; Giannakopoulos P; Morbelli S; Nobili F; Perneczky R; Didic M; Guedj E; Drzezga A; Ossenkoppele R; Berckel BV; Ratib O; Frisoni GB
Curr Alzheimer Res; 2020; 17(13):1186-1194. PubMed ID: 33583380
[TBL] [Abstract][Full Text] [Related]
27. Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer's disease.
Buchert R; Wilke F; Chakrabarti B; Martin B; Brenner W; Mester J; Clausen M
J Neuroimaging; 2005 Oct; 15(4):348-55. PubMed ID: 16254400
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
Foster NL; Heidebrink JL; Clark CM; Jagust WJ; Arnold SE; Barbas NR; DeCarli CS; Turner RS; Koeppe RA; Higdon R; Minoshima S
Brain; 2007 Oct; 130(Pt 10):2616-35. PubMed ID: 17704526
[TBL] [Abstract][Full Text] [Related]
29. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.
Foster NL; Wang AY; Tasdizen T; Fletcher PT; Hoffman JM; Koeppe RA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S29-36. PubMed ID: 18631997
[TBL] [Abstract][Full Text] [Related]
30. Brain fluorodeoxyglucose (FDG) PET in dementia.
Kato T; Inui Y; Nakamura A; Ito K
Ageing Res Rev; 2016 Sep; 30():73-84. PubMed ID: 26876244
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a new expert system for fully automated detection of the Alzheimer's dementia pattern in FDG PET.
von Borczyskowski D; Wilke F; Martin B; Brenner W; Clausen M; Mester J; Buchert R
Nucl Med Commun; 2006 Sep; 27(9):739-43. PubMed ID: 16894329
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance.
Matsunari I; Samuraki M; Chen WP; Yanase D; Takeda N; Ono K; Yoshita M; Matsuda H; Yamada M; Kinuya S
J Nucl Med; 2007 Dec; 48(12):1961-70. PubMed ID: 18006622
[TBL] [Abstract][Full Text] [Related]
33. Validation of
Presotto L; Ballarini T; Caminiti SP; Bettinardi V; Gianolli L; Perani D
Neuroinformatics; 2017 Apr; 15(2):151-163. PubMed ID: 28063108
[No Abstract] [Full Text] [Related]
34. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease.
Okamura N; Arai H; Higuchi M; Tashiro M; Matsui T; Hu XS; Takeda A; Itoh M; Sasaki H
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Feb; 25(2):447-56. PubMed ID: 11294488
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies.
Dukart J; Mueller K; Horstmann A; Vogt B; Frisch S; Barthel H; Becker G; Möller HE; Villringer A; Sabri O; Schroeter ML
Neuroimage; 2010 Jan; 49(2):1490-5. PubMed ID: 19770055
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
[TBL] [Abstract][Full Text] [Related]
37. Qualitative and Quantitative Analyses of Brain 18Fluoro-Deoxy-Glucose Positron Emission Tomography in Primary Progressive Aphasia.
Nuvoli S; Tanda G; Stazza ML; Madeddu G; Spanu A
Dement Geriatr Cogn Disord; 2019; 48(5-6):250-260. PubMed ID: 32062656
[TBL] [Abstract][Full Text] [Related]
38. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
39. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions.
Burns CM; Kaszniak AW; Chen K; Lee W; Bandy DJ; Caselli RJ; Reiman EM
J Alzheimers Dis; 2018; 62(2):833-840. PubMed ID: 29480176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
